The company was awarded a patent on its method of producing human collagen in plants.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at firstname.lastname@example.org.
Shares in CollPlant Holdings Ltd. (TASE: CLPT) rose strongly on the Tel Aviv Stock Exchange this morning after the US Patent and Trademark Office approved a patent related to the company’s collagen production method.
CollPlant develops and produces medical products based on recombinant human collagen. The company announced today that the US Patent Office had approved its patent protecting methods of producing human collagen in plants. This gives CollPlant a competitive advantage in advance of the launch of its products in the US.
“The US represents one of the company’s strategic target markets, and we see the strengthening and consolidation of our intellectual property in this territory as a significant achievement, ” CollPlant CEO Yehiel Tal said.
Besides the patent on its method of production of collagen in plants, CollPlant also has patents protecting its core technology in the UU, the EU, China, Japan, Australia, South Africa, India, Mexico, New Zealand, and Singapore.